Hematocrit influences immunoassay performance for the measurement of tacrolimus in whole blood

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 766-769

  Armendáriz, Yolanda ^a   García, Sarela ^a   Lopez, Rosa M ^b   Pou, Leonor ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

EMIT; Hematocrit; MEIA; Tacrolimus

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG MONITORING; DRUG RESEARCH; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; ARTICLE; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METHODOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY;

DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOCRIT; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 33646833268     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000185769.36878.00     Document Type: Conference Paper

References (17)

1. Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001;7:242-250.
2. Kershner RP, Fitzsimmons WE. Relationship of FK-506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
3. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet. 1995;29:404-430.
4. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34:9-16.
5. Keevil BG, McCann SJ, Cooper DP, et al. Evaluation of a rapid microscale for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2002;39:487-492.
6. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002;24:59-67.
7. Kuzuya T, Ugura Y, Motegi Y, et al. Interference of hematocrit in the Tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit. 2002;24:507-511.
8. Homma M, Tomita T, Yuzawa K, et al. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull. 2002;25:1119-1120.
9. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-377.
10. Taylor PJ. Tacrolimus measurement by microparticle enzyme immunoassay. Ther Drug Monit. 2003;25:259-260.
11. Brunet M, Pou L, Manzanares C, et al. Multicenter comparison of first-and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation. Ther Drug Monit. 1998;20:676-679.
12. Vidal E, Bullich S, Pou L, et al. Tacrolimus determination by EMIT 2000 assay in clinical transplantation. Quím Clín. 2003;22:191.
13. Akbas SH, Ozdem S, Caglar S, et al. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. Clin Biochem. 2005;38:552-557.
14. Mac Farlane GD, Scheller DG, Ersfeld DL, et al. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK-506) in whole blood. Clin Chem. 1999;45:1449-1458.
15. Tomita T, Homma M, Yuzawa K, et al. Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring. Ther Drug Monit. 2005;27:94-97.
16. Alsina J. Strategies to minimize nephrotoxicity associated to calcineurin inhibitors. In Cochat P, ed. Immunosuppression Under Trial, 89-99. London: Kluwer Academic Publishers, 1999.
17. Linder MW, Elin RJ. Implications of methodologic bias for therapeutic drug monitoring. Arch Pathol Lab Med. 1999;123:931-932.